Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of HSK36273 in Healthy Subjects
NCT05742126Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of frunexian in thrombosis and thromboembolism (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Treatment Emergent Adverse Events. Started Apr 2022; status: completed.
02
Drugs
frunexian
03
Conditions
thrombosisthromboembolism
Beyond the preview
Go deeper on NCT05742126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05742126.